

Crystallization and preliminary crystallographic studies of arginine kinase from the ciliate *Paramecium tetraurelia*

Yumeto Otsuka^{†1}, Daichi Yano^{†2}, Junko Tanaka¹, Kouji Uda², Tomohiko Suzuki², Shigeru Sugiyama^{2*}

¹ Graduate School of Science, Kochi University, Kochi 780-8520, Japan

² Faculty of Science & Technology, Kochi University, Kochi 780-8520, Japan

[†] These authors contributed equally to this work.

* Correspondence e-mail: ssugiyama@kochi-u.ac.jp

KEYWORDS. *arginine kinase, protein crystallization, X-ray crystallography*

ABSTRACT: The arginine kinase from the ciliate *Paramecium tetraurelia* catalyzes the reversible transfer of phosphoryl groups from adenosine triphosphate to arginine, generating adenosine diphosphate and arginine phosphate. The ciliate *Paramecium tetraurelia* has four arginine kinases (*PtAK1* to *4*). *PtAK3* showed typical substrate inhibition toward arginine, and the enzymatic activity markedly decreased when the arginine concentration increased. To elucidate the substrate inhibition mechanism of *PtAK3*, we performed a crystallographic study of *PtAK3*. Here we report the crystallization and preliminary X-ray diffraction analysis of *PtAK3*. The diffraction data were collected and processed with a 2.6 Å resolution based on the *PtAK3* crystals. The preliminary crystallographic analysis revealed that the *PtAK3* crystals belonged to the orthorhombic space group $P2_12_12_1$, with unit-cell parameters $a = 77.5$, $b = 162.5$, $c = 68.8$ Å. They contained two molecules per asymmetric unit.

1. Introduction

Phosphagen kinases (PKs) are enzymes that catalyze the reversible transfer of the γ -phosphoryl group of adenosine triphosphate (ATP) to guanidine substrates, generating adenosine diphosphate (ADP) and phosphorylated guanidine compounds referred to as phosphagens (Morrison & James, 1965). These enzymes play a key role in maintaining a constant ATP concentration, especially in cells that consume a significant amount of ATP energy (Ellington, 2001, Ellington & Suzuki 2006). Arginine kinase (AK), a member of the phosphagen kinase family, is widely distributed in invertebrates (Uda *et al.*, 2006), including unicellular organisms such as bacteria (Andrews *et al.*, 2008; Suzuki *et al.*, 2013) and protozoan ciliates (Uda *et al.*, 2006; Magida & Fraga, 2007). Substrate inhibition is the phenomenon where enzymes are inhibited by their own substrate. This occurs approximately for 20% of all enzymes (Chaplin & Bucke, 1990) and often has important biological functions (Kuehl, 1994; Reed *et al.*, 2010).

The ciliate *Paramecium tetraurelia* contains four types of arginine kinase (*PtAK1* to *PtAK4*). In a previous study (Yano *et al.*, 2017), we showed that *PtAK3* is characterized by typical arginine substrate inhibition and that enzymatic activity markedly decreased with a concentration of 1 mM arginine substrate (Yano *et al.*, 2017; Yano & Suzuki, 2018). Substrate inhibition in wild-type PKs was first observed with *PtAK3*. In these same studies—by using three models—the substrate inhibition kinetics of wild-type and mutant *PtAK3* were also

analyzed to understand the various occurring mechanisms. The results suggested that after primary arginine substrate binding, the binding of another arginine at the secondarily induced inhibitory site is accelerated to form the two substrate-enzyme complex, causing substrate inhibition (Yano & Suzuki, 2018). In the current study, we conducted a crystallographic investigation to elucidate the reaction mechanism of *PtAK3* at the atomic level.

2. Materials and Methods

2.1. Crystallization

Recombinant *PtAK3* was purified according to the protocol described previously (Yano *et al.*, 2017). The resulting recombinant *PtAK3* was dialyzed in 10 mM Tris-HCl (pH 8.0). For crystallization, the purified *PtAK3* solution was concentrated to 18 mg/ml by the ultrafiltration method using an Amicon Ultra-4 concentrator (Merck, USA). The purity was verified by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) on 12.5% gels (Laemmli, 1970). A preliminary search for crystallization conditions was performed using the sitting-drop method in 24-well Cryschem plates (Hampton Research, USA). Initial crystallization screening conditions were constructed using several commercially available kits:




Figure 1.

A 12.5% SDS-PAGE of purified *PtAK3*. The gel was stained with Coomassie Brilliant Blue. Lane M, molecular-mass markers (labelled in kDa); Lane 1, purified *PtAK3*.

Received: May 5, 2019

Reviewed by anonymous referee(s), and accepted: May 31, 2019

Published: July 24, 2019

Crystal Screen and Crystal Screen 2 (both from Hampton Research, USA). Typically, a 1.0 μl droplet consisting of 18 mg/ml *PtAK3* in 10 mM Tris-HCl (pH 8.0) and 1 mM dithiothreitol was mixed with an equal volume of reservoir solution. This droplet was allowed to equilibrate against 500 μl of reservoir solution. All crystallizations were carried out at 285 K.

2.2. X-ray data collection

Data collection was performed with the beamline BL26B1 of the SPring-8 synchrotron-radiation source (Hyogo, Japan). The crystals were soaked in a cryoprotectant solution and then mounted in a cryoloop. The crystal was immediately flash-cooled in a stream of nitrogen gas at 100 K. Diffraction data sets were collected using 0.5° oscillations with a crystal-to-detector distance of 200 mm. The diffraction data were processed and scaled using the *HKL-2000* program package (Otwinowski & Minor, 1997).




Figure 2. Crystal of *PtAK3* prepared by sitting-drop vapour diffusion.

3. Results and Discussion

Purified *PtAK3*—with a calculated molecular weight of 44.6 kDa—migrated as a single band on the matrix gel using SDS-PAGE. The analysis showed a homogeneous preparation with a molecular weight of 45 kDa (Fig. 1). A preliminary search for crystallization conditions was performed using Hampton Crystal Screens. Microcrystals of *PtAK3* were obtained as clusters from several PEG-based reagents. The crystals from the cluster exhibited poor diffraction quality and were too small for diffraction experiments. The use of a seeding technique in an attempt to improve the crystals proved unsuccessful. Therefore, we tried to further refine the crystallization conditions. Consequently, the crystallization conditions were optimized by changing the PEG concentration and the pH. As a result, suitable *PtAK3* crystals with dimensions of $0.02 \times 0.02 \times 0.2$ mm appeared at 285 K within a week. The best crystallization condition for X-ray diffraction measurement

was obtained with a reservoir solution consisting of 20% (w/v) PEG4000 and 0.1 M Hepes-NaOH (pH 7.0). The crystallization condition is summarized in Table 1.

Table 1. Crystallization conditions

Method	Sitting-drop vapour diffusion
Plate type	24-well plate
Temperature (K)	285
Protein concentration (mg/ml)	10
Buffer composition of protein solution	10 mM Tris-HCl (pH 8.0), 1.0 mM DTT
Composition of reservoir solution	0.1 M Hepes-NaOH (pH 7.0), 20% (w/v) PEG4000
Volume and ratio of drop	2 μl , 1:1 (protein solution: reservoir solution)
Volume of reservoir (μl)	900

Table 2. Crystal parameters and data-collection statistics for *PtAK3*.

Values in parentheses are for the outer shell.

X-ray source	SPring-8 (BL26B1)
Wavelength (\AA)	0.90
Temperature (K)	100
Detector	Eiger 4M CCD
Crystal-to-detector distance (mm)	200
Rotation range per image ($^\circ$)	0.5
Total rotation range ($^\circ$)	211.5
Exposure time per image (s)	20
Space group	$P2_12_12_1$
Unit-cell parameters	
a, b, c (\AA)	77.5, 162.5, 68.8
α, β, γ ($^\circ$)	90, 90, 90
Mosaicity ($^\circ$)	0.29
Resolution range (\AA)	50 - 2.60
(High-resolution shell)	(2.64- 2.60)
Total No. of reflections	150025
No. of unique reflections	24813
Completeness (%)	88.4 (74.1)
Multiplicity	6.0 (3.6)
Mean $I/\sigma(I)$	4.4 (1.7)
R_{merge}^{\S} (%)	18.6 (56.3)
Overall B factor from Wilson plot (\AA^2)	24.8

$\S R_{\text{merge}} = \frac{\sum_{hkl} \sum_i |I_i(hkl) - \langle I(hkl) \rangle|}{\sum_{hkl} \sum_i I_i(hkl)}$, where $I_i(hkl)$ is the i th observed intensity of reflection hkl and $\langle I(hkl) \rangle$ is the average intensity over symmetry-equivalent measurements.

X-ray diffraction experiments were performed under a stream of nitrogen gas at 100 K. A crystal was mounted in a nylon loop, soaked rapidly in the 15% (v/v) glycerol, 20% (w/v) PEG4000, 0.1 M Hepes-NaOH (pH 7.0) and then immediately flash-cooled. The wavelength was fixed at 0.9 \AA . A total of 423 frames were recorded with an oscillation angle of 0.5° , an exposure time of 20 s per frame and a crystal-to-detector distance of 200 mm. Diffraction data were processed and scaled using the *HKL-2000* program package (Otwinowski & Minor, 1997). Analysis of the symmetry and the systematic absences in the recorded diffraction pattern indicated that the crystals belonged to the cubic space group $P2_12_12_1$, with unit-cell parameters $a = 77.5$, $b = 162.5$, $c = 68.8$ \AA . Assuming the presence of two *PtAK3* molecules (2×45 kDa) in the asymmetric unit, the V_M value is calculated to be 3.1 $\text{\AA}^3\text{Da}^{-1}$, with an estimated solvent content of 49.4 %; these values are

within the range commonly observed for protein crystals (Matthews, 1968). Calculation of the Matthews coefficient suggested that two monomers exist in the asymmetric unit. A total of 150025 observed reflections were merged into 24813 unique reflections in the 50.0-2.6 Å resolution range. Data-collection and processing statistics are summarized in Table 2. Structural analysis of the *PtAK3* is now in progress. We anticipate that our structural study of the *PtAK3* will contribute to elucidation of the substrate inhibition mechanism of the *PtAK3*.

Acknowledgements

The authors are grateful to Seiki Baba, Nobuhiro Mizuno, Akifumi Higashiura, Eiki Yamashita, and Atsushi Nakagawa for their kind help in data collection at BL26B1 and BL44XU of SPring-8. The synchrotron-radiation experiments were performed at SPring-8 with the approval of the Japan Synchrotron Radiation Research Institute (JASRI; Proposals 2016A/B6623, 2017B2516 2018A/B6824, and 2018A/B2509). This work was supported in part by the Takahashi Industrial and Economic Research Foundation and by JSPS KAKENHI grant Nos. 16K07270 and 19K06588 to SS.

References

- Andrews, L.D., Graham, J., Snider, M.J., & Fraga, D., *Comp. Biochem. Physiol. B Biochem. Mol. Biol.*, **150**, 312–319 (2008).
- Chaplin, M., & Bucke, C., *Enzyme Technology (Chapter 1: Fundamentals of Enzyme Kinetics)*, Cambridge University Press, Cambridge, (1990).
- Ellington, W.R., *Ann. Rev. Physiol.*, **63**, 289–325 (2001).
- Ellington, W.R., & Suzuki, T., In: Vial C (ed) *Molecular anatomy and physiology of proteins: creatine kinase*. Nova Science, New York, pp 1–27 (2006).
- Kuehl, P.W., *Biochem. J.*, **298**, 171–180 (1994).
- Magida, L., & Fraga, D., *FASEB J.*, **21**, A299 (2007).
- Matthews, B.W., *J. Mol. Biol.*, **33**, 491–497 (1968).
- Morrison, J.F., & James, E., *Biochem. J.*, **97**, 37–52 (1965).
- Otwinowski & Minor, W., *Methods Enzymol.*, **276**, 307–326 (1997).
- Reed, M.C., Lieb, A., & Nijhout, H.F., *Bioessays*, **32**, 422–429 (2010).
- Suzuki, T., Soga, S., Inoue, M., & Uda, K., *Int. J. Biol. Macromol.*, **57**, 273–277 (2013).
- Uda, K., Fujimoto, N., Akiyama, Y., Mizuta, K., Tanaka, K., Ellington, W.R., & Suzuki, T., *Comp. Biochem. Physiol. Part D Genomics Proteomics*, **1**, 209–218 (2006).
- Yano, D., Suzuki, T., Hirokawa, S., Fuke, K., & Suzuki, T., *Int. J. Biol. Macromol.*, **101** 653–659 (2017).
- Yano, D., & Suzuki, T., *Protein J.*, **37**, 581–588 (2018).
- Laemmli, U.K., *Nature*, **227**, 409–413 (1970)